310.582.7900

Clinical Trial List

The Angeles Clinic & Research Institute is currently enrolling participants in clinical trials for:

Basal Cell Carcinoma

A Pivotal Phase II, Multicenter, Single Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients with Advanced Basel Cell Carcinoma

Go back to the top

Brain Tumors

The Temodar Combination Study

Go back to the top

Breast Cancer

A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

An Open-Label, Randomized, Adaptive Design, Two-Period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet

An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anti-Cancer Treatment in Patients with Solid Tumors.

Go back to the top

Lung Cancer

APRICOT-L :  A Randomized, Double Blind, Placebo Controlled Multicenter
Phase 2Study of the Efficay and Safety of Apricoxib in Combination with Erlotinib in Non-Small Lung Cancer Patients

Go back to the top

Melanoma

Adjuvant Therapy

A Randomized, Double-Blind Phase III Trial of Adjuvant Immunotherapy with Ipilimumab vs. Placebo After Complete Resection of High-Risk Stage III Melanoma 

A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 ASCI as Adjuvant Therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma

Melanoma - First Line Therapy

An Open, Single-Arm Trial to Assess the Clinical Activity of recMAGE-A3 + AS15 in Patients with Unresectable MAGE-A3-Positive Stage III or Stage IVA Metastatic Cutaneous Melanoma

A Study of RO5185426 (BRAF therapy) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

A Phase Ib/II Study of ALT-801 with Cisplatin in Patients with Metastatic Melanoma

Melanoma – Second Line Therapy

A Randomized, Phase III Study of LY573636 (Tasisulam) Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma

Melanoma – Pretreated/Any Line

A Phase I, Open-Label, Dose-Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Melanoma

A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

A Phase II, Open Label, NonRandomized Study to Evaluate the Safety, Tolerability, Immune Response, and Clinical Response of Multiple Doses of MKC1106-MT in Subjects with Advanced Melanoma

A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma

A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors

A Phase I, Multicenter, Open Label, Dose Escalation, Safety Study of E6201 in subjects with Advanced Solid Tumors

Melanoma - Brain Metastasis

A Phase II Trial of Temozolomide plus Bevacizumab in Patients with Metastatic Melanoma Involving the Central Nervous System

Melanoma – Acral and Mucosal

A Phase II study of Imatinib (Gleevec) in Patients with Mucosal or Acral/Lentiginous Melanoma or Melanomas that arise on Chronically Sun Damaged Skin

A Phase II Study of Sentinel Therapy for Patients with Metastatic Melanoma and KIT Gene Aberrations

A Phase II Study of Nilotinib in TKI Resistant or Intolerant Patients with Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Go back to the top

Prostate Cancer

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer

A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects

A Randomized, Double-Blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel

Go back to the top

Phase I / Any Tumor

A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors

A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination with Either Gemcitabine, Cisplatin, or Carboplatin in Adult Patients With Advanced Solid Tumors

An Open-Label, Randomized, Adaptive Design, Two-Period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet

An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anti-Cancer Treatment in Patients with Solid Tumors

A Phase I, Multicenter, Open Label, Dose Escalation, Safety Study of E6201 in subjects with Advanced Solid Tumors

Ovarian cancer

Colorectal Cancer

Pancreatic Cancer

Gastointestinal Cancer

Go back to the top

Santa Monica Office
2001 Santa Monica Blvd, Suite 560W
Santa Monica, CA 90404
West Los Angeles Office
11818 Wilshire Blvd.
Los Angeles, CA 90025